Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, April 19, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

SEATTLE - Shareholders say directors of Dendreon Corp. dumped $9.5 million of their own shares at prices inflated by false statements about its major product, an expensive cancer drug called Provenge, and that Dendreon's market cap sank 72% in a day when the truth came out.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...